Business Context and Reporting Period
Company: Neurocrine Biosciences, Inc.
Filing Type: Form 8-K (Current Report)
Report Date: July 30, 2025
Reporting Period: Second Quarter ended June 30, 2025
Context: This filing announces the financial results for the second quarter of 2025. The detailed results are contained in a press release attached as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover page and index for the Form 8-K and does not contain specific financial data. The following metrics are not present in the source text:
- Revenue: Not provided.
- Profit/Loss: Not provided.
- Cash Flow: Not provided.
- Margins: Not provided.
- Debt and Liquidity: Not provided.
Material Changes
The filing text does not provide specific numerical comparisons or descriptions of material changes versus the prior comparable period. Investors must refer to Exhibit 99.1 for this analysis.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, risk factors, or details on contingencies and unusual items. These disclosures are expected to be found in the attached press release (Exhibit 99.1).
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated July 30, 2025) for actual revenue, net income, and cash flow figures.
- Verify year-over-year and quarter-over-quarter growth rates in the attached press release.
- Check for any updates to full-year 2025 financial guidance within the press release.
- Confirm the status of key product launches or clinical trial milestones mentioned in the full announcement.